Сrystagen
Biologically active food supplement CRYSTAGEN® is a peptide complex containing amino acids: glu-
tamic acid, aspartic acid, and proline, which has a normalizing effect on the cells of the immune system.
CRYSTAGEN® is available in tablets or capsules with an active substance content of 0.100 mg.
CRYSTAGEN® regulates metabolic processes in the cells of the immune system, restores impaired
immunological reactivity, and stimulates regeneration processes in case of their suppression. Experi-
mental studies have shown that peptides have a tissue-specific effect on the cells of those tissues from
which they are isolated. Thus, it is possible to extrapolate the efficiency of KRYSTAGEN® to restore
the function of the immune system in various pyoinflammatory and other diseases characterized by
the suppression of the immune status of patients.
It is known that various factors of physical, chemical, and biological nature, depending on the duration
and intensity of their impact on the human body, can lead to depletion of adaptive and compensatory
mechanisms and cause profound disorders of various segments of the immune defense system (2, 3).
Pathological disorders in the immune system usually result in a long-term course of the basic disease
with a tendency to relapse, a decrease in the body’s resistance to infection, and the development of
severe complications.
Among the drugs that contribute to the restoration of immunological reactivity are immunomodulators
of various origins: enzyme medication (trypsin, lysozyme), bacterial polysaccharides (pyrogenal, pro-
digiosan), yeast polysaccharides (zymosan, glucans, propermil, dextrans), vaccines (BCG), nucleic acid
medication ( sodium nucleinate), purine and pyrimidine derivatives, levamisole, diucifon, traditional
medicine, and many others (1, 2).
Clinical trials of СRYSTAGEN® were carried out in the period from November 2005 to February 2006
at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology of the North-
west Branch of the Russian Academy of Medical Sciences, in patients after long-term exposure to low
doses of ionizing radiation, including cancer patients after radiation and chemotherapy.
The primary group consisted of 40 patients (23 men, 17 women), who, in addition to conventional
treatments, were prescribed CRYSTAGEN® 1-3 capsules 2-3 times a day before meals for 15-20 days,
depending on the severity of immune status disorders. Patients in the control group received only
general-purpose medication.
The age of patients in both groups ranged from 38 to 69 years. The distribution of patients by noso-
logical forms, sex, and age is presented in Table 1.
Distribution of patients by nosological forms, sex and age. Table 1
Diagnosis Age (years) Men Women Total
Control group Primary Control group Primary Control group Primary
group group group
State after low-dose 38-56 10 14 5 6 15 20
ionizing radiation
influence
State after radiation 43-69 8 9 7 11 15 20
and chemotherapy in
oncological patients
Total 18 23 12 17 30 40
RESEARCH RESULTS
СRYSTAGEN® efficiency was assessed by changes of the patients’ complaints and by the number
of objective parameters: General clinical analysis of blood and urine, the immunological study of
peripheral blood (the number of T- and B-lymphocytes was determined by the immunofluorescence
method with monoclonal antibodies to differentiation lymphocyte antigens CD3, CD4, CD8, CD20;
the content of immunoglobulins of various classes - by the method of radial immunodiffusion in gel
according to Mancini; functional activity of T-lymphocytes - using leukocyte migration inhibition test
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.